Novo and Sanofi make case for hypo-reducing insulins at EASD

Novo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals trying to make the case for their competing insulins and their ability t

Janssen's MS pill outshines Sanofi's Aubagio in phase 3 tria...

Johnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio pill in adults with relapsing multiple sclerosis.

Who will be the biggest pharma players in orphan drugs?

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.

Mylan’s Lantus biosimilar held up by manufacturing issue

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9...

Sanofi's eczema drug gets EU approval to treat adolescents

The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron's eczema drug Dupixent (dupilumab) to include adolescents, while new phase 3